Repotrectinib

瑞普替尼

Report date: 2026/02/26 20:00:22
NME

Base Information

Drug NameRepotrectinib
Drug Alias Name洛普替尼RopotrectinibAugtyro奥凯乐TPX-0005 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProto-oncogene tyrosine-protein kinase ROS inhibitorsNerve growth factor receptor Trk-A inhibitorsNeurotrophic tyrosine kinase receptor type 2 inhibitors +[4] 
TargetsProto-oncogene tyrosine-protein kinase ROSNerve growth factor receptor Trk-ANeurotrophic tyrosine kinase receptor type 2 +[4] 
Therapy Area/IndicationsBrain metastasesSolid tumoursHepatic Insufficiency +[7] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryUnited States
Original Approved Date2023/11/15
Country/TerritoryBelgiumCanadaUnited States +[29] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTurning Point Therapeutics Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyZai Lab (Shanghai) Co LtdInstituto Oncológico Dr. Rosell +[8] 
Inactive CompaniesZai Lab LtdMemorial Sloan Kettering Cancer CenterZai Lab (Suzhou) Co Ltd
Active IndicationsBrain metastasesSolid tumoursHepatic Insufficiency +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG